Citation Impact
Citing Papers
Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study
2008 Standout
Perioperative Chemotherapy Compared With Surgery Alone for Resectable Gastroesophageal Adenocarcinoma: An FNCLCC and FFCD Multicenter Phase III Trial
2011 Standout
Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update 2014
2015 Standout
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations
2013 Standout
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
2008 Standout
Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance
2018 Standout
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
2007 Standout
Randomized Phase III Trial of Weekly Compared With Every-3-Weeks Paclitaxel for Metastatic Breast Cancer, With Trastuzumab for all HER-2 Overexpressors and Random Assignment to Trastuzumab or Not in HER-2 Nonoverexpressors: Final Results of Cancer and Leukemia Group B Protocol 9840
2008
Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents
2012
Smarter drugs emerging in pancreatic cancer therapy
2014
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
2017 Standout
American Gastroenterological Association Institute Guideline on the Prevention and Treatment of Hepatitis B Virus Reactivation During Immunosuppressive Drug Therapy
2014
Breast cancer
2016 Standout
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial
2014 Standout
Management of patients with hepatitis B who require immunosuppressive therapy
2013
Management of viral hepatitis in patients with haematological malignancy and in patients undergoing haemopoietic stem cell transplantation: recommendations of the 5th European Conference on Infections in Leukaemia (ECIL-5)
2016
The biology and management of non-small cell lung cancer
2018 StandoutNature
Potential for primary prevention of Alzheimer's disease: an analysis of population-based data
2014 Standout
Role of platelet-derived growth factors in physiology and medicine
2008 Standout
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2016 Standout
The Risks and Benefits of 5α-Reductase Inhibitors for Prostate-Cancer Prevention
2011
Lung Cancer
2008 Standout
Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer
2015 StandoutNature
The resurgence of platinum-based cancer chemotherapy
2007 Standout
HIF2α cooperates with RAS to promote lung tumorigenesis in mice
2009 StandoutNobel
Management of elderly patients with breast cancer: updated recommendations of the International Society of Geriatric Oncology (SIOG) and European Society of Breast Cancer Specialists (EUSOMA)
2012
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
2010
Influence of tumour micro-environment heterogeneity on therapeutic response
2013 StandoutNature
Bevacizumab
2007
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
2006 Standout
Poor Recognition of Risk Factors for Hepatitis B by Physicians Prescribing Immunosuppressive Therapy: A Call for Universal Rather than Risk-Based Screening
2015
Monetary Costs of Dementia in the United States
2013 Standout
American Gastroenterological Association Institute Technical Review on Prevention and Treatment of Hepatitis B Virus Reactivation During Immunosuppressive Drug Therapy
2014
An atlas of genetic correlations across human diseases and traits
2015 Standout
IgG4-Related Disease
2012 Standout
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
2014 StandoutNature
Targeted therapies in bladder cancer: an overview of in vivo research
2015
Mechanisms of NAFLD development and therapeutic strategies
2018 Standout
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2010 Standout
Testicular germ-cell tumours in a broader perspective
2005 Standout
Oesophageal carcinoma
2013 Standout
Intraoperative Electron Radiotherapy (IOERT) as an Alternative to Standard Whole Breast Irradiation: Only for Low-Risk Subgroups?
2014
Bladder cancer
2016 Standout
Hindlimb Suspension and SPE-Like Radiation Impairs Clearance of Bacterial Infections
2014 StandoutNobel
Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer
2007 Standout
The potential of anti-vascular endothelial growth factor therapy in metastatic breast cancer: Clinical experience with anti-angiogenic agents, focusing on bevacizumab
2008
Microtubule-binding agents: a dynamic field of cancer therapeutics
2010 Standout
Early prediction of treatment response to high-dose salvage chemotherapy in patients with relapsed germ cell cancer using [18F]FDG PET
2002
VEGF-targeted therapy: mechanisms of anti-tumour activity
2008 Standout
Targeting the ERBB family in cancer: couples therapy
2013
Coinhibitory Receptor Expression and Immune Checkpoint Blockade: Maintaining a Balance in CD8+ T Cell Responses to Chronic Viral Infections and Cancer
2017 StandoutNobel
IgG4-related disease
2014 Standout
Prevention of Hepatitis B reactivation in the setting of immunosuppression
2016
Trends in hepatitis B virus screening at the onset of chemotherapy in a large US cancer center
2013
Palbociclib and Letrozole in Advanced Breast Cancer
2016 Standout
Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial
2012
Insomnia as a predictor of depression: A meta-analytic evaluation of longitudinal epidemiological studies
2011 Standout
Low Risk of Hepatitis B Virus Reactivation in HBsAg-negative/Anti-HBc–positive Carriers Receiving Rituximab for Rheumatoid Arthritis: A Retrospective Multicenter Italian Study
2016
Modes of resistance to anti-angiogenic therapy
2008 Standout
The projected effect of risk factor reduction on Alzheimer's disease prevalence
2011 Standout
Biomarkers for Early Detection and as Surrogate Endpoints in Cancer Prevention Trials: Issues and Opportunities
2010
Tumor Angiogenesis
2008 Standout
Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis
2012
Molecular biology and targeted therapies for urothelial carcinoma
2015
Drug Resistance and the Solid Tumor Microenvironment
2007 Standout
Rituximab for the Treatment of IgG4-Related Disease
2011
Hepatitis B Virus Reactivation and Prophylaxis During Solid Tumor Chemotherapy
2015
AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease
2023 Standout
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
2018 Standout
Spectrum of Activity and Mechanism of Action of VEGF/PDGF Inhibitors
2007
Screening for Prostate Cancer: U.S. Preventive Services Task Force Recommendation Statement
2012 Standout
EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection
2017 Standout
The MAPK pathway across different malignancies: A new perspective
2014 Standout
Hepatitis B reactivation in HBsAg‐negative/HBcAb‐positive patients receiving rituximab for lymphoma: a meta‐analysis
2015
Screening for prostate cancer
2013
Risk of Venous Thromboembolism in Patients With Cancer Treated With Cisplatin: A Systematic Review and Meta-Analysis
2012
Ipilimumab Administration in Patients With Advanced Melanoma and Hepatitis B and C
2013
Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer: AVAiL
2009
Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune‐suppressing and anticancer drugs: Just the tip of the iceberg?
2014
Low Rates of Hepatitis B Virus Screening at the Onset of Chemotherapy
2012
Antimicrobial Prophylaxis and Outpatient Management of Fever and Neutropenia in Adults Treated for Malignancy: American Society of Clinical Oncology Clinical Practice Guideline
2013
Multicenter Phase II Study of Irinotecan, Cisplatin, and Bevacizumab in Patients With Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
2006
Cancer Genome Landscapes
2013 StandoutScience
Factors Affecting Wound Healing
2010 Standout
Bevacizumab Plus Irinotecan in Recurrent Glioblastoma Multiforme
2007 Standout
Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor–Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance)
2016
Chemotherapy triggers HIF-1–dependent glutathione synthesis and copper chelation that induces the breast cancer stem cell phenotype
2015 StandoutNobel
Pharmacogenetic Assessment of Toxicity and Outcome After Platinum Plus Taxane Chemotherapy in Ovarian Cancer: The Scottish Randomised Trial in Ovarian Cancer
2007
Works of Robin Zoň being referenced
Phase II Trial of Cisplatin, Gemcitabine, and Bevacizumab As First-Line Therapy for Metastatic Urothelial Carcinoma: Hoosier Oncology Group GU 04-75
2011
National Institutes of Health State-of-the-Science Conference Statement: Diagnosis and Management of Ductal Carcinoma In Situ September 22-24, 2009
2010
Management strategies and outcomes of germ cell tumor patients with very high human chorionic gonadotropin levels.
1998
A meta-analysis of overall survival data from three randomized trials of bevacizumab (BV) and first-line chemotherapy as treatment for patients with metastatic breast cancer (MBC).
2010
Use of 5α-Reductase Inhibitors for Prostate Cancer Chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline
2009
American Society of Clinical Oncology Provisional Clinical Opinion: Chronic Hepatitis B Virus Infection Screening in Patients Receiving Cytotoxic Chemotherapy for Treatment of Malignant Diseases
2010
ASCO Provisional Clinical Opinion: Chronic Hepatitis B Virus Infection in Patients Receiving Cytotoxic Chemotherapy for Treatment of Malignant Diseases
2010
Randomized phase II trial of panitumumab, erlotinib, and gemcitabine (PGE) versus erlotinib-gemcitabine (GE) in patients with untreated, metastatic pancreatic adenocarcinoma.
2011
Hoosier Oncology Group Randomized Phase II Study of Docetaxel, Vinorelbine, and Estramustine in Combination in Hormone-Refractory Prostate Cancer with Pharmacogenetic Survival Analysis
2006
A randomized phase III trial of paclitaxel with or without bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer: Eastern cooperative oncology group trial E2100
2006
Use of 5-α-Reductase Inhibitors for Prostate Cancer Chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline
2009